- Home
- SYRE
as 10-24-2025 3:54pm EST
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.1B | IPO Year: | 2016 |
| Target Price: | $57.60 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.91 - $40.26 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Spyre Therapeutics Inc. (SYRE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Burrows Scott L | SYRE | Chief Financial Officer | Sep 2 '25 | Sell | $16.26 | 18,428 | $299,639.28 | 97,994 |
Latest Spyre Therapeutics Inc. News
SYRE Breaking Stock News: Dive into SYRE Ticker-Specific Updates for Smart Investing
GlobeNewswire
20 days ago
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
GlobeNewswire
22 days ago
Spyre Therapeutics Announces Grants of Inducement Awards
Simply Wall St.
a month ago
Spyre Therapeutics (SYRE) Doses First Patient In Promising SPY072 Phase 2 Trial
GlobeNewswire
a month ago
Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
PR Newswire
4 months ago
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts
PR Newswire
4 months ago
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025
PR Newswire
5 months ago
Spyre Therapeutics Announces Grants of Inducement Awards
PR Newswire
5 months ago
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
Compare SYRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SYRE Spyre Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.